FHTX Q1 2021 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$322M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$286,000

Gross Profit

-$18M-6447.6% margin

Operating Income

-$23M-8087.4% margin

Net Income

-$23M-8037.1% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

+13.9%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$25M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$230M

Total Liabilities

$105M

Stockholders' Equity

$125M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$286,000	$0	—
Gross Profit	-$18M	$0	—
Operating Income	-$23M	-$14M	-68.5%
Net Income	-$23M	-$14M	-64.8%